Tenon Medical 10% holder nets 17,785-share sale

Q: What insider trading activity did HRT FINANCIAL LP report for TNON?

HRT FINANCIAL LP, a ten percent owner of TNON, reported a series of open-market purchases and sales of Tenon Medical common stock between September 8 and 10, 2026, with more shares sold than bought over that period.

Q: How many TNON shares did HRT FINANCIAL LP buy and sell?

Across the reported period, HRT FINANCIAL LP bought 108,140 shares and sold 125,925 shares of Tenon Medical common stock, resulting in a net of 17,785 more shares sold than bought according to the transaction summary.

Q: What prices were paid and received in the TNON insider trades?

Reported TNON trade prices ranged from $2.61 to $5.56 per share, including purchases such as 31,227 shares at $2.92 and sales such as 65,582 shares at $5.56, all described as open-market or private transactions.

Q: Was a Rule 10b5-1 trading plan used for these TNON insider transactions?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming plan use, and no footnote describes a trading plan, so the transactions are reported without reference to a pre-established Rule 10b5-1 plan.

A ten percent owner of TNON reported mixed open-market trades over three days, with more shares sold than bought and some positions resulting in short sales.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Tenon Medical, Inc. (TNON) reported that HRT FINANCIAL LP, a ten percent owner, executed multiple open-market transactions in its common stock from September 8–10, 2026. The firm purchased 108,140 shares and sold 125,925 shares, for a net of 17,785 more shares sold than bought.

Reported prices ranged from $2.61 to $5.56 per share, including purchases such as 31,227 shares at $2.92 and sales such as 65,582 shares at $5.56. A footnote states that the transactions with the related note resulted in short sales. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 17,785 shares

Net Sell 8 txns

Insider HRT FINANCIAL LP

Role 10% Owner

Bought 108,140 shs ($383K)

Sold 125,925 shs ($539K)

Type	Security	Shares	Price	Value
Purchase	Common Stock ^{F1, F2}	31,227	$2.92	$91K
Purchase	Common Stock ^{F1, F2}	28,267	$4.02	$114K
Purchase	Common Stock ^{F1, F2}	8,431	$4.92	$41K
Sale	Common Stock ^{F1, F2}	65,582	$5.56	$365K
Sale	Common Stock ^{F1, F2}	50,395	$2.61	$132K
Purchase	Common Stock ^{F1, F2}	39,508	$3.40	$134K
Sale	Common Stock ^{F1, F2}	9,948	$4.27	$42K
Purchase	Common Stock ^F1	707	$3.34	$2K

Holdings After Transaction: Common Stock — 15,839 shares (Direct)

Footnotes (2)

F1. We will provide, upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
F2. Resulting in short sales.

Key Figures

Shares purchased: 108,140 shares Shares sold: 125,925 shares Net shares sold: 17,785 shares +5 more

8 metrics

Shares purchased 108,140 shares Total TNON common shares purchased by HRT FINANCIAL LP over September 8–10, 2026

Shares sold 125,925 shares Total TNON common shares sold by HRT FINANCIAL LP over September 8–10, 2026

Net shares sold 17,785 shares Net of shares sold over shares bought, reported as net-sell

Largest single purchase 31,227 shares at $2.92 per share Purchase of TNON common stock on September 10, 2026

Largest single sale 65,582 shares at $5.56 per share Sale of TNON common stock on September 10, 2026

Price range of trades $2.61–$5.56 per share Lowest and highest reported prices across all TNON transactions

Additional purchase 39,508 shares at $3.40 per share Purchase of TNON common stock on September 9, 2026

Additional sale 50,395 shares at $2.61 per share Sale of TNON common stock on September 9, 2026

Key Terms

ten percent owner, short sales, open market or private transaction

3 terms

ten percent owner regulatory

"HRT FINANCIAL LP is identified as a ten percent owner of Tenon Medical"

short sales financial

"A footnote for certain transactions states they were resulting in short sales"

Short sales are trades where an investor borrows shares and sells them immediately, aiming to buy them back later at a lower price and return them to the lender; the profit is the difference if the price falls. This matters to investors because short selling can signal negative expectations about a company, add downward pressure on a stock’s price, and carries unlimited loss risk if the stock rises instead of falls—like betting a borrowed item will be cheaper to replace later.

open market or private transaction financial

"Each trade is described as a purchase or sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider trading activity did HRT FINANCIAL LP report for TNON?

HRT FINANCIAL LP, a ten percent owner of TNON, reported a series of open-market purchases and sales of Tenon Medical common stock between September 8 and 10, 2026, with more shares sold than bought over that period.

How many TNON shares did HRT FINANCIAL LP buy and sell?

Across the reported period, HRT FINANCIAL LP bought 108,140 shares and sold 125,925 shares of Tenon Medical common stock, resulting in a net of 17,785 more shares sold than bought according to the transaction summary.

What prices were paid and received in the TNON insider trades?

Reported TNON trade prices ranged from $2.61 to $5.56 per share, including purchases such as 31,227 shares at $2.92 and sales such as 65,582 shares at $5.56, all described as open-market or private transactions.

Were any of HRT FINANCIAL LP's TNON trades short sales?

Yes. A footnote attached to several transactions states they were “resulting in short sales”, indicating that those particular purchases and sales created or adjusted short positions in Tenon Medical common stock.

Was a Rule 10b5-1 trading plan used for these TNON insider transactions?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirming plan use, and no footnote describes a trading plan, so the transactions are reported without reference to a pre-established Rule 10b5-1 plan.

On which dates did HRT FINANCIAL LP trade TNON shares?

The reported transactions in Tenon Medical common stock occurred on September 8, 9, and 10, 2026, with multiple purchases and sales recorded on September 9 and 10.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/11/2026 - 02:14 PM EDT Accepted by SEC EDGAR 09/11/2026 - 02:13 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HRT FINANCIAL LP

(Last)

(First)

(Middle)

3 WORLD TRADE CENTER, 175 GREENWICH STRE

76TH FLOOR

(Street)

NEW YORK

10007

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tenon Medical, Inc. [ TNON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/08/2026		P		707	A	$3.34⁽¹⁾	2,653	D
Common Stock	09/09/2026		S		50,395	D	$2.61⁽¹⁾	18,182⁽²⁾	D
Common Stock	09/09/2026		P		39,508	A	$3.4⁽¹⁾	18,182⁽²⁾	D
Common Stock	09/09/2026		S		9,948	D	$4.27⁽¹⁾	18,182⁽²⁾	D
Common Stock	09/10/2026		P		31,227	A	$2.92⁽¹⁾	15,839⁽²⁾	D
Common Stock	09/10/2026		P		28,267	A	$4.02⁽¹⁾	15,839⁽²⁾	D
Common Stock	09/10/2026		P		8,431	A	$4.92⁽¹⁾	15,839⁽²⁾	D
Common Stock	09/10/2026		S		65,582	D	$5.56⁽¹⁾	15,839⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. We will provide, upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

2. Resulting in short sales.

	Adam Nunes	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR